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            Amendments from Version 1
1.    Colour clarification of genotypes from cross in Figure 1.
2.    Changed t-tests to non-parametric tests (Mann-Whitney U) in 
Figure 3 for qPCR and western blot experiments as normal 
distribution of data could not be tested or assumed due to 
sample sizes being too low.
3.    Changed text in results and discussion to agree with 
reviewers that protein data is only preliminary and future 
studies should test for ZBTB20 protein changes in multiple 




The Tg(PDGFB-APPSwInd)20Lms (MGI:3057148, here 
referred to as ‘J20’) mouse model is a transgenic animal that 
overexpresses mutant human APP protein (amyloid precursor 
protein), and is widely used as a model of amyloid deposition 
and pathogenesis in the study of Alzheimer’s disease (AD). J20 
mice recapitulate many AD-like phenotypes, including synaptic 
loss, amyloid plaque deposition and cognitive impairment 
(Hong et al., 2016; Mucke et al., 2000; Palop & Mucke, 2016).
The model was developed by Mucke and colleagues using the 
PDGF-APPSw,Ind transgene construct described previously 
(Games et al., 1995; Rockenstein et al., 1995), which includes a 
human APP mini-gene, carrying the familial AD-linked 717V-F 
(Indiana) mutation (Murrell et al., 1991) and 670/671KM-NL 
(Swedish) double mutation (Mullan et al., 1992). The transgene 
construct was designed so that the APP mini-gene included 
genomic sequence for APP introns 6–8, allowing expression 
of hAPP695, hAPP751 and hAPP770 isoforms. The PDGF- 
APPSw,Ind transgene expression is driven in neurons 
throughout the brain by the human platelet-derived growth 
factor β chain (PDGFβ) promoter (Harris et al., 2010; Sasahara 
et al., 1991). The J20 mouse is an important model: currently, 
125 articles have been catalogued in the Mouse Genome 
Database bibliography (Blake et al., 2017), which report geno-
typic and/or phenotypic data from this mouse. This strain has 
been used for several classical genetic studies to determine the 
interaction of genes of interest with the APP transgene including 
a seminal report of the importance of Tau to Aß-associated 
neuronal dysfunction (Roberson et al., 2007). Moreover, this 
model has been used to elucidate the role of Aß in synaptic 
dysfunction (Palop & Mucke, 2016; Palop et al., 2007; Sanchez 
et al., 2012).
Transgenic mice are conventionally generated by direct injection 
of linear foreign DNA into the pronucleus of fertilised zygotes. 
Once inside the cell, these linear fragments undergo circu-
larisation and concatemer formation before integrating into 
the host genome as a tandem array (Bishop & Smith, 1989). In 
principle, transgenes insert randomly into the host genome; 
however, ∼45% of integration sites lie within host gene 
regions (∼13.2 exonic, 31.6% intronic), potentially as a result 
of increased accessibility of transcriptionally active DNA (Yan 
et al., 2013). Integration of a transgene array into coding 
sequences can induce new mutations (for example, haploinsuffi-
ciency) (Haruyama et al., 2009), and so it is important to know 
the site of integration for a transgene array in a mouse model.
A recent study suggested an association of a heterozygous 
deletion of the CHMP2B gene (charged multivesicular body 
protein 2B) with early-onset Alzheimer’s disease (Hooli et al., 
2014). Interestingly, mutations in CHMP2B are a rare genetic 
cause of Frontotemporal dementia (Skibinski et al., 2005). We 
have previously reported generation of a Chmp2b knockout 
mouse (Ghazi-Noori et al., 2012). To determine if Chmp2b 
deletion modulates APP/Aß biology in vivo, we attempted to 
cross our Chmp2b knockout with the J20 mouse, to study 
potential double mutant progeny. The Chmp2b locus lies on 
mouse chromosome 16.
Here, we present the outcome of these genetic cross experi-
ments and the resulting mapping of the J20 transgene array 
integration site by Targeted Locus Amplification (TLA) with 
deep sequencing. We discuss how integration of the transgene 
affects expression of the flanking loci.
Methods
Animal welfare
Mice were housed in controlled conditions in accordance with 
guidelines from the UK Medical Research Council in Respon-
sibility in Use of Animals for Medical Research (1993). Two 
female J20 positive animals were killed at 6 months of age to pro-
vide splenic material for the TLA study. Furthermore, 3 month 
hippocampal tissue was collected from J20 animals: N=5, 
3 male, 2 female. C57BL/6J controls: N=5, 3 male, 2 female. All 
used for qRT-PCR and western blotting. All experiments were 
conducted under license from the UK Home Office and with 
Local Ethical Review approval. Tg(PDGFB-APPSwInd)20Lms/
2Mmjax animals (J20) were obtained from The Jackson 
laboratory (stock no. 034836) and maintained on a C57BL/6J 
background in our animal facility. Chmp2b knockout animals 
were already available in our animal facility (Ghazi-Noori et al., 
2012). Mice had access to a mouse house with bedding 
material and wood chips. All animals had continual access to 
water and RM1 (Special Diet Services) (stock animals) or RM3 
(Special Diet Services) (breeding animals) chow ad libitum. 
Mice were housed in individually ventilated cages in a specific 
pathogen free facility with a 12 hour light/dark cycle.
Genotyping of J20 and Chmp2b knockout mice
DNA was extracted from tail tip or ear biopsy by the HOTSHOT 
method (Truett et al., 2000).
The presence of the J20 human APP transgene was tested by PCR 
using primers (Eurofins) APP-F: 5’-GTGAGTTTGTAAGTGAT-
GCC-3’ APP-R: 5’-TCTTCTTCTTCCACCTCAGC-3’, control 
primers ContF: 5’-CAAATGTTGCTTGTCTGGTG-3’ ContR: 
5’-GTCAGTCGAGTGCACAGTTT-3). Copy number of the human 
APP transgene was validated by quantitative PCR using a Taqman 
Fast machine (Applied Biosystems) with the following primers 
and probes: hAPPF: 5’-TGGGTTCAAACAAAGGTGCAA-3’ 
hAPPR: 5’-GATGAAGATCACTGTCGCTATGAC-3’ hAPP-
probe: FAM-CATTGGACTCATGGTGGGCGGTG-3’ qContF: 
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The Chmp2b knockout locus was detected by PCR with the 
following primers: Int2_F: 5’-CCATTGCCACTTGGATGTAA-
3’ Int2_R: 5’-GACGCACTTTAAGGTCACAGC-3’ KO_R: 
5’- TCTCTGTGCAAGAAGCATGAA-3’. PCR products were 
separated by agarose gel electrophoresis and visualised using a 
BioRad Gel Doc XR UV transilluminator.
Extraction of spleen cells from J20 animals
Mice were sacrificed by rising concentration of CO2 and 
confirmed by dislocation of the neck and the spleen dissected 
and kept on ice. Splenocytes were then dissociated through a 
40µm mesh filter and the cells collected by centrifugation at 
4°C at 500 × g for 5 minutes. The supernatant was discarded 
and the pellet re-suspended in 1 ml red blood cell lysis buffer 
(4.13g NH4Cl, 0.5g KHCO3, 193.5µl 0.5M EDTA dissolved 
in 500ml H2O) for three minutes at room temperature to lyse 
splenic erythrocytes. To terminate the lysis reaction, 0.5ml 
phosphate buffered saline (PBS) was added and the splenocytes 
were collected again by centrifugation at 500 × g for 5 minutes. 
The supernatant was discarded and the pellet re-suspended in 
0.5ml PBS before a final centrifugation step for 2 minutes. The 
supernatant was discarded and the pellet was re-suspended in 
1ml freezing buffer (PBS with 10% fetal calf serum and 10% 
dimethyl sulphoxide). Samples were stored at -80°C before 
preparation for TLA processing.
Targeted Locus Amplification
Processing of samples for TLA was performed by Cergentis 
B.V. (Utrecht, The Netherlands), as previously described 
(de Vree et al., 2014). A primer pair targeted to the APP 
transgene sequence was used to perform the TLA. Sequences of 
the PCR primers are (5’ to 3’): 1917_APP_F GAAACTCATCT-
TCACTGGCA; 1698_APP_R GGGTAGACTTCTTGGCAATA. 
PCR products were purified and library prepped using the 
Illumina NexteraXT protocol and sequenced on an Illumina 
Miniseq sequencer.
Sequence alignment and analysis of TLA
TLA reads were mapped using BWA-SW, which is a Smith-
Waterman alignment tool. This allows for partial mapping, which 
is optimally suited for identifying break-spanning reads. The 
mouse Mm10 genome assembly version was used for mapping. 
Visualisation and interpretation of the data were performed 
using the Integrative Genomics Viewer (IGV) from the Broad 
Institute (Robinson et al., 2011).
RNA extraction and quantitative reverse transcription PCR
RNA was extracted from whole hippocampus from J20 
animals and age and litter matched controls. Total RNA was 
extracted using the Qiagen miRNeasy kit and reverse transcribed 
using the Applied Biosystems High-Capacity RNA-to-cDNA™ 
Kit.
Quantitative RT-PCR was carried out on the Zbtb20 gene tran-
script using a predesigned PrimeTime® probe-based qPCR assay 
(assay ID: Mm.PT.58.41805451, Integrated DNA Technologies 
[IDT]) targeted to exons 8–9 (RefSeq transcript NM_181058) 
with a FAM probe. TaqMan reactions were run with Taqman 
Universal Master Mix 2 on a 7500 Fast machine (Applied 
Biosystems) using standard cycling conditions. Transcript levels 
were normalised against Applied Biosystems mouse Actb (Assay 
ID: 4352933E) and Integrated DNA Technologies B2m (assay 
ID: Mm.PT.39a.22214835) endogenous controls in independent 
experiments and the results averaged geometrically. Both controls 
contained VIC probes.
Tissue preparation and western blotting for ZBTB20
For analysis of ZBTB20 in hippocampus, J20 and age/sex- 
matched wildtype littermate controls were dissected under ice-
cold PBS before homogenisation in radioimmunoprecipitation 
buffer (150mM sodium chloride, 50mM Tris, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate) with 
Protease Inhibitor Cocktail Set 1 (Merck). Total protein concen-
tration was determined using Bradford assay (Bio-Rad). Samples 
from individual animals were run separately and not pooled.
Equal amounts of hippocampal brain proteins were denatured in 
LDS sample buffer (ThermoFisher) and β-Mercaptoethanol for 
10 minutes at 100°C, prior to separation by SDS polyacryla-
mide gel electrophoresis in 4–12% pre-cast gels (ThermoFisher). 
Separated proteins were transferred to 0.2µm nitrocellulose 
membrane and blocked in 5% milk/phosphate buffered saline 
(with 0.05% Tween 20, PBST) for one hour at room tempera-
ture. The membrane was then cut horizontally at the 49KDa 
band (SeeBlue Plus II protein ladder, Invitrogen) and the lower 
half was incubated in mouse monoclonal antibody to β-Actin 
(A5441, Sigma-Aldrich) diluted 1:200,000 in 1% bovine serum 
albumin (BSA)/PBST overnight at 4°C. The upper half was 
incubated overnight with rabbit polyclonal primary antibody 
against ZBTB20 (23987-1-AP, ProteinTech) diluted 1:1000 in 
1% BSA/PBST. After washing with PBST the upper and lower 
membranes were incubated with HRP-conjugated secondary 
rabbit and mouse antibodies, respectively, diluted in 1% BSA/
PBST for 1 hour at room temperature. SuperSignal™ West 
Pico Chemiluminescent Substrate and X-ray film was used to 
visualise bands, Image J 1.49c software (NIH) was used to 
analyse band intensity. Graphpad prism 5 (Graphpad Software, 
Inc.) was used to plot graphs and SPSS 25 (IBMCorp) was 
used to perform statistical analyses.
Results
Mouse breeding strategy
To investigate the role of Chmp2b in the pathogenesis of AD, 
we attempted to generate a homozygous knockout of Chmp2b in 
the Tg(PDGFB-APPSwInd)20Lms (J20) APP transgenic mouse 
strain. To accomplish this we set up matings over two genera-
tions (Figure 1a), firstly between Chmp2b-/- and hemizygous 
J20 mice (referred for simplicity as TgAPPJ20/-, where ‘J20’ 
denotes the presence of the transgene). This cross produced 
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Chmp2b+/-;TgAPPJ20/- and Chmp2b+/-;TgAPP-/- progeny. In the 
second stage, the Chmp2b+/-;TgAPPJ20/- offspring were crossed 
to Chmp2b-/- null animals. This cross was predicted to produce 
four progeny genotypes at equal Mendelian ratios (0.25): 
(i) homozygous for Chmp2b knockout, without the 
APP transgene (Chmp2b-/-;TgAPP-/-),
(ii) homozygous for Chmp2b knockout, hemizygous for 
APP transgene (Chmp2b-/-;TgAPPJ20/-),
(iii) hemizygous for Chmp2b knockout, hemizygous for 
APP transgene (Chmp2b+/-;TgAPPJ20/-),
(iv) hemizygous for Chmp2b knockout, without the APP 
transgene (Chmp2b+/-;TgAPP-/-).
The second stage cross resulted in 76 progeny, but the observed 
ratio of genotypes significantly differed from the expected 
ratio (Figure 1b). Strikingly no Chmp2b-/-;TgAPPJ20/- progeny 
were produced. This suggests that either Chmp2b-/-;TgAPPJ20 
may not be viable or the TgAPP allele might be on the same 
chromosome as Chmp2b - mouse chromosome 16 (Mmu16), 
preventing typical Mendelian segregation.
Targeted locus Amplification analysis of J20 transgene 
insertion
To determine the cause of the absence of Chmp2b-/-;TgAPPJ20 
offspring, we mapped the site of the J20 TgAPP transgene 
insertion, and so sequenced flanking regions around the 
insertion site by TLA. Sequence analysis (Figure 2a) showed 
that the TgAPP insertion site lies on Mmu16. Targeted reads 
mapped the integration breakpoints to genomic co-ordinates 
Mmu16: 43,127,050 (3’ end of the transgene array) and 
Mmu16: 43,127,512 (5’ end of the transgene array). In addition, 
sequencing around the insertion site revealed a 41.17kb 
deletion in the mouse genome between chr16:43,085,979 and 
chr16:43,127,149 (Figure 2b). Thus the lack of Chmp2b-/-;TgAPPJ20 
offspring is the result of the insertion of TgAPPJ20 on Mmu16, 
explaining the absence of Chmp2b-/-;TgAPPJ20 progeny from the 
stage 2 cross.
TLA also allowed us to assess transgene sequence integrity. 
We found three SNPs (hAPP transgene sequence: 624 G > A, 
979 G > A, 10649 G > A) and four indels (TG: 185 G > +1T, TG: 
1168 G > +8GGCGGGAC, TG: 1423 C > +1G, TG: 5932 C > -1T) 
within the integrated transgene construct; however, all were 
silent mutations or found within intronic sequence. Furthermore, 
TLA analysis showed at least one transgene copy is truncated at 
the 3’ end (TG: 12088), ablating the ampicillin cassette, and is 
fused to the 5’ of another transgene copy to form a concatemer 
(TG:12088 fused to TG:3).
Assessment of ZBTB20 expression
The integration site co-ordinates localize the J20 transgene 
insertion and deletion entirely within intron 1 of the gene 
Figure 1. Breeding scheme and observed ratios of offspring in a two-generation cross between Chmp2b-/- and J20+/- animals. (A) Two-
generation breeding scheme to generate Chmp2b-/-; J20+/- animals. (B) Observed ratios of offspring genotype differed significantly from the 
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Figure 2. Insertion site of the J20 APP transgene (Tg) on mouse chromosome 16. (A) Representation of Mmu16 showing insertion site of 
the J20 Tg array. Also shown are the positions of endogenous mouse App and Chmp2b. (B) TLA applied to the APPSwInd transgene in the 
J20 mouse. Read mapping to the mouse (mm10) genome assembly shows the exact Tg insertion site (red arrows) with associated genomic 
deletion (yellow bar). Gene annotation is shown below labelling a small portion of intron 1 of the Zbtb20 gene. (C) TLA reads mapped to the 
APP Tg sequence. Complete coverage was achieved, showing that head to tail concatemerization of the Tg has occurred at position 12088 
ablating the ampicillin cassette of the plasmid construct. Coloured lines represent SNPs found in the Tg sequence compared to the published 
sequence. A linearised map of the plasmid construct is shown below.
Zinc-finger and BTB domain containing 20 (Zbtb20, transcript 
NM_001285805.1) on Mmu16. Zbtb20 is a member of the 
BTB/POZ family of transcriptional repressors and functions 
primarily as a transcriptional repressor (Xie et al., 2008); it is 
important for hippocampal development and function, the site 
of greatest Aβ deposition in aging J20 animals (Mucke et al., 
2000). Moreover, missense mutations in this gene are associated 
with Primrose syndrome, a cause of intellectual disability with 
autism (Cordeddu et al., 2014; Mattioli et al., 2016). Additionally, 
haploinsufficiency of the gene has been suggested as an 
important factor in del3q13.31 syndrome, a cause of developmen-
tal delay and intellectual disability (Rasmussen et al., 2014). To 
determine whether transgene insertion has affected Zbtb20 
transcription in J20 animals in hippocampal tissue, we investi-
gated mRNA and protein levels of ZBTB20 in wildtype and J20 
animals.
Firstly, a predesigned RT-qPCR assay was chosen from IDT to 
overlap the exon 8–9 boundary within the protein coding region 
of the Zbtb20 transcript, downstream of the transgene inser-
tion site. Importantly this junction is present in all predicted 
RefSeq protein coding transcript isoforms. We detected signifi-
cantly less transcript in J20 animals compared to wildtype using 
this assay (Figure 3a). To determine whether reduction in Zbtb20 
transcript results in a reduction of ZBTB20 protein in J20 
animals, we assayed total hippocampal protein by western blot 
for ZBTB20 with an affinity purified polyclonal antibody, and 
observed that no change in ZBTB20 protein level in adult J20 
hippocampal tissue could be determined by this method. We 
aimed to validate this result with another antibody (ab48889, 
Abcam) however, we were unable to determine a specific band 
at the correct molecular weight (data not shown). Because of the 
postnatal lethality demonstrated in Zbtb20-/- mice (Sutherland 
et al., 2009) and the complexity in producing control adult 
Zbtb20-/- hippocampal tissue, we were not able to validate this 
result using an appropriate negative control.
Discussion
Using TLA we have located the insertion site of the J20 APP 
transgene on Mmu16 within intron 1 of the Zbtb20 gene. We 
have also found a 41kb deletion of intronic sequence flanking the 
insertion site. Due to the key role of Zbtb20 in hippocampal 
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cell differentiation and function, we determined its expression 
in hippocampal tissue, and found that while Zbtb20 transcript 
expression is reduced in J20 hippocampus, we could find no 
evidence that protein expression is altered, although we note the 
current technical limitations of our study because of the lack of 
an appropriate negative control. In a similar study investigating 
the transgene insertion site of the R6/2 Huntingdon’s disease 
model mouse, Jacobsen et al. discovered that the HTT exon 1 
transgene inserted within intron 7 of the Gm12695 gene, causing 
an almost 30 fold increase of expression of this gene compared 
to wildtype in cortical tissue irrespective of CAG-repeat length 
polymorphisms, showing that the genomic aberration caused by 
foreign DNA insertion within intronic sequence can alter gene 
regulation (Jacobsen et al., 2017). Notably, disruption of the 
expression of nearby genes may also occur in gene-targeted 
systems. For example, two of the four lines of mice that are 
null for the Prion protein gene Prnp, exhibited late onset ataxia 
and neurodegeneration -- this was subsequently found to be the 
result of aberrant upregulation of a gene (Prnd) downstream 
of Prnp, which occurred as a result of induced exon skipping 
(Moore et al., 1999). In the J20 model, hippocampal Zbtb20 
transcription is perturbed without concomitant protein reduction. 
This is perhaps not as surprising as it seems; recent data 
indicate mRNA levels explain only around 40% of vari-
ability in protein levels (Wilhelm et al., 2014), with protein 
abundance being primarily dependent on translational control 
(Schwanhäusser et al., 2011; Schwanhäusser et al., 2013).
It may be important to assess expression in multiple neuro-
nal cell types and other tissues throughout development in the 
J20 model, considering that ectopic expression of Zbtb20 in the 
subiculum and post-subiculum results in aberrant CA1 type devel-
opment in those regions with associated CA1-specific markers 
(Nielsen et al., 2010) and the gene has been shown to have a 
role in liver function (Sutherland et al., 2009). The transgene 
sequence itself is intact in the J20, excluding several single 
nucleotide mutations; however, these are either silent or found 
within the transgene construct’s three intronic regions and 
are unlikely to affect the J20 transgene. TLA analysis and 
in-house copy number qPCR (data not shown) indicate that this 
transgene has integrated multiple times in an array on Mmu16. 
Multiple transgene insertion may be liable to recombination 
events, causing loss of some copies of the transgene, resulting in 
delayed onset of phenotype in affected animals. This potential 
confound can be allayed by undertaking a genomic copy-number 
qPCR to confirm copy-number consistency between individuals. 
The Jackson Laboratory have published their assay for general 
use.
Genetic engineering can result in unintended disruption of the 
genome, which can confound interpretation of phenotype if the 
genomic alterations cause changes in protein expression. Trans-
genic models have been and continue to be powerful tools for 
biomedical research, but knowledge of the insertion site and the 
local effects on gene expression will inform phenotyping studies.
Data availability
Aligned BAM files from the TLA, uncropped western blot for 
Figure 3B, hippocampal qPCR data and western blot data for 
Zbtb20 are available on OSF http://doi.org/10.17605/OSF.
IO/4UGZF (Tosh, 2017).
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Figure 3. Expression of Zbtb20 mRNA and protein in 3 month old wildtype and J20+/- hippocampus. (A) Zbtb20 mRNA expression is 
significantly reduced in J20 hippocampus compared to wildtype (WT), detected by quantitative RT-PCR using primers spanning exons 8–9 
(Mann Whitney U = 1, n = 5 wildtype/6 J20. P = 0.009). (B) ZBTB20 protein levels are unchanged in J20 hippocampus compared to wildtype 
animals (Mann-Whitney U = 10, n = 5 wildtype/4 J20, P = 1). Sample sizes were too low to test for normality so non-parametric testing was 
conducted. Error bars show standard error of the mean; uncropped blots can be viewed at http://doi.org/10.17605/OSF.IO/4UGZF.
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